nano-cannabidiol

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• anxiety [Insufficient Evidence]
• aphthous ulcer (canker sores) [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• atopic dermatitis (eczema) [Insufficient Evidence]
• bipolar disorder [Insufficient Evidence]
• cachexia, cancer-related [Insufficient Evidence]
• cannabis use disorder [Insufficient Evidence]
• cocaine dependence [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• Crohn dz [Insufficient Evidence]
• dementia [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• dyspepsia [Insufficient Evidence]
• dystonia [Insufficient Evidence]
• epilepsy [Likely Effective]
• essential tremor [Insufficient Evidence]
• exercise-induced muscle damage [Insufficient Evidence]
• exercise-induced muscle soreness [Insufficient Evidence]
• fatigue, cancer-related [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• fragile X syndrome [Insufficient Evidence]
• gastroparesis [Insufficient Evidence]
• graft-versus-host dz [Insufficient Evidence]
• HTN [Insufficient Evidence]
• Huntington dz [Insufficient Evidence]
• IBS [Insufficient Evidence]
• insomnia [Insufficient Evidence]
• multiple sclerosis [Insufficient Evidence]
• nausea/vomiting, chemo-induced [Insufficient Evidence]
• nephrolithiasis [Insufficient Evidence]
• neuropathic pain [Insufficient Evidence]
• obesity [Insufficient Evidence]
• opioid withdrawal [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• pain, acute [Insufficient Evidence]
• pain, cancer-related [Insufficient Evidence]
• pain, chronic [Insufficient Evidence]
• pain, postop [Insufficient Evidence]
• peripheral neuropathy [Insufficient Evidence]
• post-traumatic stress disorder [Insufficient Evidence]
• psoriatic arthritis [Insufficient Evidence]
• psychological well-being [Insufficient Evidence]
• psychosis, acute [Insufficient Evidence]
• psychosis, Parkinson dz-assoc. [Insufficient Evidence]
• rapid eye movement sleep behavior disorder [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• smoking cessation [Insufficient Evidence]
• social anxiety disorder [Insufficient Evidence]
• taste changes, chemo-related [Insufficient Evidence]
• temporomandibular disorder [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]

Info: cannabidiol (CBD) nonpsychoactive constituent is typically derived from marijuana or hemp, two forms of Cannabis sativa; for combined THC and CBD herbal extract info see 'cannabis'; for FDA-approved Rx product see 'cannabidiol (CBD)' (oral purified CBD); all other preparations are not FDA-approved

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

anxiety

[Insufficient Evidence (PO route)]

Dose: 200-800 mg CBD PO qd; Start: 200 mg CBD PO qd, then may titrate to optimal dose; Max: 800 mg/day

[Insufficient Evidence (SL route)]

Dose: 9.97 mg CBD solution SL tid; Info: solution containing low level THC 0.69 mg/day

aphthous ulcer (canker sores)

[Insufficient Evidence]

Dose: apply 0.1% CBD patch topically tid

atopic dermatitis (eczema)

[Insufficient Evidence]

Dose: apply 1% CBD gel topically qd

cannabis use disorder

[Insufficient Evidence]

Dose: 400-800 mg/day CBD oil PO divided bid

cognitive function

[Insufficient Evidence]

Dose: 9.97 mg CBD solution SL tid; Alt: 12.5 mg (5% CBD) via inhalation x1

dementia

[Insufficient Evidence]

Dose: 11.8-247.8 mg CBD oil SL tid; Start: 11.8 mg CBD oil SL tid, then titrate to optimal dose; Info: cannabis oil containing 295 mg/mL CBD and 12.5 mg/mL THC

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 200 mcg CBD spray SL q12h; Info: given 30min before meals; product containing 100 mcg/spray CBD and 10 mcg/spray THC

dystonia

[Insufficient Evidence]

Dose: 100-600 mg CBD PO qd

exercise-induced muscle damage

[Insufficient Evidence]

Dose: 60 mg CBD PO x1; Start: after exercise

fragile X syndrome

[Insufficient Evidence]

Dose: apply 50-250 mg/day CBD gel topically divided qd-bid; Alt: apply 125 mg CBD gel topically q12h if wt <35 kg; apply 250 mg CBD gel topically q12h if wt >35 kg; Info: for use in peds pts

epilepsy, adult pts

[Likely Effective]

Dose: apply 195-390 mg (4.2% CBD gel) topically bid

epilepsy, peds pts

[Likely Effective]

Dose: apply 125-500 mg (4.2% CBD gel) topically bid; Info: for pts 3-18 yo

graft-versus-host dz

[Insufficient Evidence]

Dose: 150 mg CBD oil PO bid; Start: 7 days before transplant; Info: used w/ standard tx

HTN

[Insufficient Evidence]

Dose: 225-300 mg/day CBD PO divided bid-tid x2.5wk, then titrate to 375-450 mg/day CBD PO divided bid-tid x2.5wk; Alt: 150 mg CBD PO q8h

insomnia

[Insufficient Evidence]

Dose: 15 mg CBD PO qd

osteoarthritis

[Insufficient Evidence]

Dose: apply 6.2 mg CBD cream topically bid

pain, chronic

[Insufficient Evidence]

Dose: 15 mg CBD PO bid; Alt: apply 10 mg CBD cream topically bid

pain, postop

[Insufficient Evidence]

Dose: 25 mg CBD buccally tid if wt <80 kg; 50 mg CBD buccally tid if wt >80 kg

post-traumatic stress disorder

[Insufficient Evidence]

Dose: 300 mg CBD PO x1

psychological well-being

[Insufficient Evidence]

Dose: 150 mg CBD oil PO bid; Alt: 15 mg CBD oil PO qd

psychosis, Parkinson dz-assoc.

[Insufficient Evidence]

Dose: 150 mg CBD PO qd x1wk, then incr. by 150 mg/day qwk if tolerated; Alt: 300 mg CBD PO x1

peripheral neuropathy

[Insufficient Evidence]

Dose: apply oil topically to affected areas; Info: oil contains CBD, camphor and eucalyptus leaf

schizophrenia

[Insufficient Evidence]

Dose: 400 mg CBD PO qid; Alt: 1000 mg PO qd; Info: used w/ or w/o standard tx

smoking cessation

[Insufficient Evidence]

Dose: 400 mcg/actuation CBD via inhalation prn; Alt: 320 mg CBD PO x1

social anxiety disorder

[Insufficient Evidence]

Dose: 300-600 mg CBD PO x1; Alt: 300 mg CBD PO qd

taste changes, chemo-related

[Insufficient Evidence]

Dose: 300 mg CBD PO qd x8 days; Info: given during each cycle of chemo

temporomandibular disorder

[Insufficient Evidence]

Dose: apply 20% CBD ointment topically bid